Medical Centre for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University, 121 Jiangjiayuan Road, Nanjing, 210046, China.
Department of Gastroenterology, Lianyungang No 1 People's Hospital, Lianyungang, China.
J Cancer Res Clin Oncol. 2023 Oct;149(13):12297-12313. doi: 10.1007/s00432-023-05116-z. Epub 2023 Jul 11.
Gallbladder cancer (GC) is a uncommon and highly malignant tumor. This study compared the effects of simple cholecystectomy (SC) and extended cholecystectomy (EC) on the long-term survival of stage I GC.
Patients with stage I GC between 2004 and 2015 in the SEER database were selected. Meanwhile, this study collected the clinical information of patients with stage I GC admitted to five medical centers in China between 2012 and 2022. Using clinical data from patients in the SEER database as a training set to construct a nomogram, which was validated in Chinese multicenter patients. Long-term survival between SC and EC were distinguished using propensity score matching (PSM).
A total of 956 patients from the SEER database and 82 patients from five Chinese hospitals were included in this study. The independent prognostic factors were age, sex, histology, tumor size, T stage, grade, chemotherapy and surgical approach by multivariate Cox regression analysis. We developed a nomogram based on these variables. The nomogram has been proved to have good accuracy and discrimination in internal and external validation. The cancer-specific survival (CSS) and overall survival of patients receiving EC were better than those of SC before and after the propensity score match. The interaction test showed that EC was associated with better survival in patients aged ≥ 67 years (P = 0.015) and in patients with T1b and T1NOS (P < 0.001).
A novel nomogram to predict CSS in patients with stage I GC after SC or EC. Compared with SC, EC for stage I GC had higher OS and CSS, especially in specific subgroups (T1b, T1NOS, and age ≥ 67 years).
胆囊癌(GC)是一种罕见且高度恶性的肿瘤。本研究比较了单纯胆囊切除术(SC)和扩大胆囊切除术(EC)对 I 期 GC 患者长期生存的影响。
从 SEER 数据库中选择 2004 年至 2015 年间患有 I 期 GC 的患者。同时,本研究收集了 2012 年至 2022 年间中国五家医疗中心收治的 I 期 GC 患者的临床信息。使用 SEER 数据库中患者的临床数据作为训练集构建列线图,并在中国多中心患者中进行验证。使用倾向评分匹配(PSM)区分 SC 和 EC 之间的长期生存。
本研究共纳入了来自 SEER 数据库的 956 例患者和来自五家中国医院的 82 例患者。多因素 Cox 回归分析显示,独立的预后因素为年龄、性别、组织学、肿瘤大小、T 分期、分级、化疗和手术方式。我们基于这些变量开发了一个列线图。该列线图在内部和外部验证中均具有良好的准确性和区分度。在倾向评分匹配前后,接受 EC 的患者的癌症特异性生存(CSS)和总生存(OS)均优于接受 SC 的患者。交互检验显示,EC 与年龄≥67 岁(P=0.015)和 T1b 和 T1NOS 患者(P<0.001)的生存改善相关。
本研究建立了一个预测 SC 或 EC 后 I 期 GC 患者 CSS 的新列线图。与 SC 相比,EC 治疗 I 期 GC 的 OS 和 CSS 更高,尤其是在特定亚组(T1b、T1NOS 和年龄≥67 岁)中。